Aymen I. Idris MSc. Ph.D.

Senior Lecturer, University of Sheffield.

E Mail - aymen.idris@sheffield.ac.uk

 

Previous Positions:

Lecturer in cancer associated bone disease, University of Edinburgh.

Postdoctoral Fellow, Universities of Edinburgh and Aberdeen.

PhD student, University of Aberdeen. 

 

 

 

   

 

 
     

 

 

   

 

 
     

 

 

   

 

 
     

 

Research History

My vision is to develop a better understanding of signalling pathways that regulate bone – immune – cancer cell crosstalk in inflammation and cancer.


The specific aims of my group’s research at the University of Sheffield are to (a) uncover novel druggable pro-inflammatory signal transduction pathways essential for the regulation of malignant - bone - immune cell interactions, and (b) develop and test new anti-inflammatory agents for the prevention and treatment of skeletal and non-skeletal complications associated with cancer in patients with advanced disease. My team at the University of Sheffield currently comprises of 1 postdoctoral research fellow and 4 Ph.D. and 2 MSc. students.


My Bone and Cancer Group at the Edinburgh Cancer Research UK Centre, University of Edinburgh (2010 – 2014), developed a model system to study the role of pro-inflammatory mediators in the regulation of bone, immune and cancer cell crosstalk in vitro, ex vivo and in animal models of metastatic bone disease. Our expertise in these model systems have aided us to uncover novel pathways that play a key role in the regulation of bone - cancer cell interaction, and led to testing and development of a number of small molecule inhibitors of NF
KB activity for the treatment of rheumatoid arthritis and osteolysis. During this period, I have supervised 2 postdoctoral research fellows and 4 Ph.D. students with great success. My work in the area of cancer associated bone disease has produced 3 last-author articles published in JBMR, JBC and Br. J. Pharmacology, 1 first-author article published in Molecular Cancer Therapeutics and 6 abstracts.

 
In my early postdoctoral training period working at the University of Edinburgh (2005 – 2010) and in Professor S. Ralston’s group at the University of Aberdeen (2001 - 2005), the focus of my research was the discovery of novel anti-resorptive agents for the prevention and treatment for excessive bone loss. My PhD thesis yielded a number of patents for novel anti-resorptive agents and my work on the role of cannabinoids in bone biology was published in a number of reputable journals including Nature Medicine and Cell Metabolism, and attracted significant funding. During this period, I published 16 original research articles, 3 reviews and 2 book chapters. I was awarded the Ian Boyle award and received an AMGEN/ECTS Fellowship. I won 5 young investigator awards, received numerous travel awards, and submitted 16 abstracts to international conferences - 13 of which were chosen for oral presentations.

Selected publications

C